Literature DB >> 27253998

Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.

Frances E Carr1, Phillip W L Tai1, Michael S Barnum1, Noelle E Gillis1, Katherine G Evans1, Thomas H Taber1, Jeffrey H White1, Jennifer A Tomczak1, Diane M Jaworski1, Sayyed K Zaidi1, Jane B Lian1, Janet L Stein1, Gary S Stein1.   

Abstract

Dysregulation of the thyroid hormone receptor (TR)β is common in human cancers. Restoration of functional TRβ delays tumor progression in models of thyroid and breast cancers implicating TRβ as a tumor suppressor. Conversely, aberrant expression of the runt-related transcription factor 2 (Runx2) is established in the progression and metastasis of thyroid, breast, and other cancers. Silencing of Runx2 diminishes tumor invasive characteristics. With TRβ as a tumor suppressor and Runx2 as a tumor promoter, a compelling question is whether there is a functional relationship between these regulatory factors in thyroid tumorigenesis. Here, we demonstrated that these proteins are reciprocally expressed in normal and malignant thyroid cells; TRβ is high in normal cells, and Runx2 is high in malignant cells. T3 induced a time- and concentration-dependent decrease in Runx2 expression. Silencing of TRβ by small interfering RNA knockdown resulted in a corresponding increase in Runx2 and Runx2-regulated genes, indicating that TRβ levels directly impact Runx2 expression and associated epithelial to mesenchymal transition molecules. TRβ specifically bound to 3 putative thyroid hormone-response element motifs within the Runx2-P1 promoter ((-)105/(+)133) as detected by EMSA and chromatin immunoprecipitation. TRβ suppressed Runx2 transcriptional activities, thus confirming TRβ regulation of Runx2 at functional thyroid hormone-response elements. Significantly, these findings indicate that a ratio of the tumor-suppressor TRβ and tumor-promoting Runx2 may reflect tumor aggression and serve as biomarkers in biopsy tissues. The discovery of this TRβ-Runx2 signaling supports the emerging role of TRβ as a tumor suppressor and reveals a novel pathway for intervention.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27253998      PMCID: PMC4967127          DOI: 10.1210/en.2015-2046

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  71 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.

Authors:  Jitesh Pratap; Amjad Javed; Lucia R Languino; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

3.  Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.

Authors:  Alessia Ciarrocchi; Simonetta Piana; Roberto Valcavi; Giorgio Gardini; Bruno Casali
Journal:  Eur J Cancer       Date:  2010-12-09       Impact factor: 9.162

4.  Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer.

Authors:  Luca Dalle Carbonare; Anna Frigo; Giuseppe Francia; Maria Vittoria Davì; Luca Donatelli; Chiara Stranieri; Paolo Brazzarola; Maria Chiara Zatelli; Fabio Menestrina; Maria Teresa Valenti
Journal:  J Clin Endocrinol Metab       Date:  2012-04-17       Impact factor: 5.958

5.  Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors.

Authors:  C J Guigon; D W Kim; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2011-03-14       Impact factor: 9.867

6.  Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis.

Authors:  Olaia Martínez-Iglesias; Susana Garcia-Silva; Stephan P Tenbaum; Javier Regadera; Fernando Larcher; Jesus M Paramio; Bjorn Vennström; Ana Aranda
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 7.  Thyroid receptor: roles in cancer.

Authors:  Ana Aranda; Olaia Martínez-Iglesias; Lidia Ruiz-Llorente; Verónica García-Carpizo; Alberto Zambrano
Journal:  Trends Endocrinol Metab       Date:  2009-08-26       Impact factor: 12.015

8.  Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression.

Authors:  Won Gu Kim; Xuguang Zhu; Dong Wook Kim; Lisa Zhang; Electron Kebebew; Sheue-Yann Cheng
Journal:  Endocrinology       Date:  2012-11-26       Impact factor: 4.736

9.  The Role of RUNX2 in Osteosarcoma Oncogenesis.

Authors:  J W Martin; M Zielenska; G S Stein; A J van Wijnen; J A Squire
Journal:  Sarcoma       Date:  2010-12-09

10.  Hypothyroidism enhances tumor invasiveness and metastasis development.

Authors:  Olaia Martínez-Iglesias; Susana García-Silva; Javier Regadera; Ana Aranda
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more
  15 in total

1.  Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Cancer Res       Date:  2020-06-17       Impact factor: 5.852

2.  Common tumor-suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Lauren M Cozzens; Sophie Kogut; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Carcinog       Date:  2021-09-17       Impact factor: 4.784

Review 3.  The emerging role of transcription factor FOXP3 in thyroid cancer.

Authors:  Zhongqin Gong; Hao Jia; Lingbin Xue; Dongcai Li; Xianhai Zeng; Minghui Wei; Zhimin Liu; Michael C F Tong; George G Chen
Journal:  Rev Endocr Metab Disord       Date:  2021-08-31       Impact factor: 6.514

Review 4.  Thyroid receptor β might be responsible for breast cancer associated with Hashimoto's thyroiditis: a new insight into pathogenesis.

Authors:  Muskaan Dhingra; Shayon Mahalanobis; Asmita Das
Journal:  Immunol Res       Date:  2022-05-13       Impact factor: 4.505

5.  Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.

Authors:  Yuxiao Xia; Xue Jiang; Yuan Huang; Qian Liu; Yin Huang; Bo Zhang; Zhanjun Mei; Dongkun Xu; Yuhong Shi; Wenling Tu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-08       Impact factor: 6.055

6.  Regulation of cancer stem cell activity by thyroid hormone receptor β.

Authors:  Woo Kyung Lee; Xuguang Zhu; Sunmi Park; Yuelin Jack Zhu; Li Zhao; Paul Meltzer; Sheue-Yann Cheng
Journal:  Oncogene       Date:  2022-03-07       Impact factor: 8.756

7.  The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Michael S Barnum; Caitlin M Beaudet; Grace Y Yu; Jennifer A Tomczak; Janet L Stein; Jane B Lian; Gary S Stein; Frances E Carr
Journal:  Horm Cancer       Date:  2019-12-21       Impact factor: 3.869

8.  Thyroid Hormone Receptor β Suppression of RUNX2 Is Mediated by Brahma-Related Gene 1-Dependent Chromatin Remodeling.

Authors:  Noelle E Gillis; Thomas H Taber; Eric L Bolf; Caitlin M Beaudet; Jennifer A Tomczak; Jeffrey H White; Janet L Stein; Gary S Stein; Jane B Lian; Seth Frietze; Frances E Carr
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

9.  Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.

Authors:  Cole D Davidson; Eric L Bolf; Noelle E Gillis; Lauren M Cozzens; Jennifer A Tomczak; Frances E Carr
Journal:  J Endocr Soc       Date:  2021-06-01

10.  MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/β-Catenin Pathway in Thyroid Cancer.

Authors:  Dongfang Bai; Haipeng Sun; Xiaodong Wang; Hongliang Lou; Jian Zhang; Xiaohong Wang; Ling Jiang
Journal:  Med Sci Monit       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.